Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David G. Elsley
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 18
- Beta
- 0.52
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 14.87
Financials
Revenue
$0.00-100.0%Net Income
$-8.64MEBITDA
$-8.93MFree Cash Flow
$-4.38MEPS (diluted)
$-0.07Shares Outstanding (diluted)
114.94M+406.1%Operating Expenses
$11.28MCash & Debt
$26.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-33.82M | $-0.39 |
| 2024 | $0.00 | $-36.68M | $-0.51 |
| 2023 | $0.00 | $-21.22M | $-0.44 |
| 2022 | $0.00 | $-22.82M | $-0.49 |
| 2021 | $62.3K | $-25.01M | $-0.73 |
| 2020 | $0.00 | $-16.20M | $-0.69 |
| 2019 | $0.00 | $-10.55M | $-0.53 |
| 2018 | $0.00 | $-15.89M | $-0.66 |
| 2017 | $0.00 | $-1.66M | $-0.07 |
Valuation
CRDLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (4)
- Newsprnewswire.com·20d ago·Neutral
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
View source ↗ - Newszacks.com·21d ago·Negative
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
View source ↗ - Newsprnewswire.com·25d ago·Negative
…uding Additional Disclosure Following Review by Staff of the Ontario Securities Commission TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces an…
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.06 per share
Typical surprise +22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.04 vs $-0.09beat
- Mon, May 11$-0.07 vs $-0.07beat
- Mon, Mar 30$-0.05 vs $-0.09beat
- Thu, Nov 13$-0.09 vs $-0.09beat
- Thu, Aug 14$-0.07 vs $-0.11beat
- Wed, May 14$-0.07 vs $-0.09beat
Estimates and results for CRDL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CRDL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.